Steve Duffy

Dr Charles Raison, the Director of Clinical Research at the Usona Institute and Professor in the Department of Psychiatry at the University of Wisconsin–Madison, talks to MPR about the potential of psilocybin as a therapy for major depressive disorder.

Asthma treatment gains approval for severe cases in pediatrics; Dovato gains expanded indication; Decision taken to remove ALS drug from market; Complete Response Letter issued for apomorphine device; At-home Mpox test kit made available.

The table below is a review of notable updates that occurred in March 2024 for investigational products in development.

Drug Pharmacologic Class Proposed Indication Status Dermatologic Disorders DFD-29 (minocycline hydrochloride; Journey Medical) Tetracycline antibiotic Treatment of adults with inflammatory lesions and erythema of rosacea. NDA accepted Endocrine Disorders Paltusotine (Crinetics Pharmaceuticals) Somatostatin receptor type 2 agonist Treatment of acromegaly. Phase 3 trial results Hematological Disorders Cevidoplenib (Oscotec) Spleen tyrosine kinase inhibitor Treatment of immune…

Drug Pharmacologic Class Indication More Information Cardiovascular Disease Opsynvi (macitentan and tadalafil) An endothelin receptor antagonist and a phosphodiesterase 5 inhibitor Treatment of pulmonary arterial hypertension in adult patients of WHO functional class II-III. Opsynvi, a Single-Tablet Combo Therapy for PAH, Gets FDA Approval Praluent (alirocumab) Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor As…

First prescription smartphone app is approved for major depressive disorder; Novel blood test to detect TBI; Zevtera has been approved for bloodstream infections; The Mpox vaccine is now commercially available; Algorithm cleared for LVEF detection.